Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Here’s What Happened

Genmab A/S (NASDAQ:GMAB)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $19.06, but opened at $19.73. Genmab A/S shares last traded at $19.76, with a volume of 304,550 shares.

Analyst Ratings Changes

A number of research analysts have weighed in on GMAB shares. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Truist Financial reduced their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Price Performance

The firm has a market capitalization of $13.11 billion, a price-to-earnings ratio of 11.38, a PEG ratio of 2.65 and a beta of 0.98. The business’s 50-day moving average price is $20.94 and its 200 day moving average price is $22.00.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several hedge funds have recently bought and sold shares of GMAB. Deep Track Capital LP bought a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $41,740,000. Brandywine Global Investment Management LLC acquired a new position in Genmab A/S during the 4th quarter worth $33,804,000. Two Sigma Advisers LP grew its stake in shares of Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after purchasing an additional 938,455 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after purchasing an additional 694,243 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.